Clinical Trial

Trial Protocol ID USOR 23170_1479-0008 *STAR*

Trial Description

Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsor

  • BOEHRINGER INGELHEIM

ClinicalTrials.gov NCT ID

  • NCT06151574